Please use this identifier to cite or link to this item:
Title: Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite
Authors: Gimenez, Alba Marina [UNIFESP]
Lima, Luciana Chagas [UNIFESP
Francoso, Katia Sanches
Denapoli, Priscila M. A. [UNIFESP
Panatieri, Raquel
Bargieri, Daniel Y.
Thiberge, Jean-Michel
Andolina, Chiara
Nosten, Francois
Renia, Laurent
Nussenzweig, Ruth S.
Nussenzweig, Victor
Amino, Rogerio
Rodrigues, Mauricio M. [UNIFESP
Soares, Irene S.
Keywords: malaria
Plasmodium vivax
recombinant vaccine
circumsporozoite protein
prime-boost regimens
Issue Date: 2017
Publisher: Frontiers Media Sa
Citation: Frontiers In Immunology. Lausanne, v. 8, p. -, 2017.
Abstract: Plasmodium vivax is the most common species that cause malaria outside of the African continent. The development of an efficacious vaccine would contribute greatly to control malaria. Recently, using bacterial and adenoviral recombinant proteins based on the P. vivax circumsporozoite protein (CSP), we demonstrated the possibility of eliciting strong antibody-mediated immune responses to each of the three allelic forms of P. vivax CSP (PvCSP). In the present study, recombinant proteins representing the PvCSP alleles (VK210, VK247, and P. vivax-like), as well as a hybrid polypeptide, named PvCSP-All epi-topes, were generated. This hybrid containing the conserved C-terminal of the PvCSP and the three variant repeat domains in tandem were successfully produced in the yeast Pichia pastoris. After purification and biochemical characterization, they were used for the experimental immunization of C57BL/6 mice in a vaccine formulation containing the adjuvant Poly(I: C). Immunization with a recombinant protein expressing all three different allelic forms in fusion elicited high IgG antibody titers reacting with all three different allelic variants of PvCSP. The antibodies targeted both the C-terminal and repeat domains of PvCSP and recognized the native protein on the surface of P. vivax sporozoites. More importantly, mice that received the vaccine formulation were protected after challenge with chimeric Plasmodium berghei sporozoites expressing CSP repeats of P. vivax sporozoites (Pb/PvVK210). Our results suggest that it is possible to elicit protective immunity against one of the most common PvCSP alleles using soluble recombinant proteins expressed by P. pastoris. These recombinant proteins are promising candidates for clinical trials aiming to develop a multiallele vaccine against P. vivax malaria.
ISSN: 1664-3224
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
File SizeFormat 
WOS000412732100001.pdf3.26 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.